Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Oligometastatic Prostate Cancer — Bridging the Gap between Localized and Metastatic Disease

May 6, 2026

[Nature Reviews Urology] Results from randomized Phase II trials support the use of metastasis-directed therapy in patients with metachronous oligometastatic prostate cancer. In parallel, prostate-directed treatments such as radiotherapy and cytoreductive radical prostatectomy are under investigation.

Molecular Insights into DDX3X-Androgen Receptor mRNA Regulation via Non-Canonical G-Quadruplex in Castration-Resistant Prostate Cancer

May 6, 2026

[Oncogene] Scientists showed that DEAD-box helicase 3 X-linked (DDX3X) colocalizes with androgen receptor (AR) mRNA in androgen receptor-low/negative CRPC cells and selectively recognizes non-canonical RNA G-quadruplex motifs within the sequence of AR mRNA.

OGDHL Promotes Prostate Cancer Progression and Regulates Neuroendocrine Marker Expression and Nucleotide Abundance

May 6, 2026

[Molecular Cancer Research] Scientists identified the metabolic enzyme oxoglutarate dehydrogenase-like (OGDHL) as an unexpected regulator of tumor growth, treatment-induced lineage plasticity, and DNA damage in prostate cancer.

Fibroblast-Mediated KRAS Activation in Double-Negative Prostate Cancer

May 6, 2026

[Cell Death & Disease] The authors demonstrated that KRAS has minimal influence during the androgen receptor (AR)-dependent stages of prostate cancer but significantly activates cancer cells when AR signaling is suppressed. Further investigation revealed that AR inhibition modifies fibroblast growth factor receptor expression in prostate cancer cells.

Single-Cell Imaging Analysis, Therapeutic Modeling, and a Phase Ib Trial Validate BCL-2 As a Target across Heterogeneous Castration-Resistant Prostate Cancer

May 1, 2026

[Signal Transduction and Targeted Therapy] Integrating single-cell level imaging analyses with mechanistic studies, preclinical therapeutic experiments, and a Phase Ib clinical trial, scientists elucidated the AR+/-BCL-2+/- prosate cancer cell subpopulation dynamics and positioned BCL-2 as a therapeutic target in heterogeneous CRPC.

2 Markey Researchers Awarded $1.9 Million to Study Treatment-Resistant Cancers

April 30, 2026

[University of Kentucky] Drs. Xia Liu and Ka Wing Fong have been awarded a combined $1.9 million from the American Cancer Society to support their respective research projects. Dr. Fong’s project targets treatment-resistant prostate cancer, and Dr. Liu’s will focus on triple-negative breast cancer, two aggressive cancer types that have few effective treatment options.

Nicotinamide N-Methyltransferase As a Therapeutic Target in Taxane-Resistant Castration-Resistant Prostate Cancer

April 30, 2026

[Cell Death Discovery] Through pulse selection of the parental cells, researchers established docetaxel- and cabazitaxel-resistant CRPC cell models and integrated different omic approaches, including transcriptomics and proteomics, to determine the molecular signatures underlying taxane resistance.

Spatial Mapping of the Precancer-to-Cancer Transition in Breast and Prostate

April 30, 2026

[Cancer Discovery] In prostate cancer, GDF15, ALDH1A3, ANPEP, and FASN were upregulated along invasive progression, and their knockdown in PC-3 cells suppressed proliferation and migration.

LMNB2 Promotes Prostate Cancer Progression and Epithelial-Mesenchymal Transition via the Wnt/β-Catenin Pathway

April 30, 2026

[Discover Oncology] The authors demonstrated that reduced expression of Lamin B2 (LMNB2) substantially impairs cellular proliferation, tumor formation ability, and the epithelial-to-mesenchymal transition phenotype in prostate carcinoma cells by interfering with Wnt/β-catenin pathway activation.

Researcher Receives Renewed Federal Grant to Develop Next-Generation Prostate Cancer Treatments

April 30, 2026

[University of Tennessee Health Science Center] Dr. Ramesh Narayanan’s team will build on the discovery of a class of experimental molecules dubbed “triple inhibitors” that can do three things at once: destroy the primary androgen receptor switch, eliminate altered versions of that switch, and block the glucocorticoid receptor backup.

USP13 Promotes Enzalutamide Resistance by Catalyzing Depolyubiquitination of PCMT1 in Prostate Cancer

April 30, 2026

[Cell Death & Disease] Researchers revealed that the deubiquitinating enzyme USP13 is up-regulated in prostate cancer (PCa) tissues and correlates with prostate cancer progression. Mechanically, USP13 directly interacts with PCMT1 and removes polyubiquitination of PCMT1 to maintain its stability, which promotes PCa cell proliferation.

mir-16-5p Mediates E2-Induced Cell Proliferation and EMT in Benign Prostate Hyperplasia

April 30, 2026

[Scientific Reports] Scientists evaluated the epithelial–mesenchymal transition (EMT) and myofibroblast proliferation in E2-induced benign prostatic hyperplasia-1 (BPH), RWPE-1, and WPMY-1 cells. Theu suggest miR-16-5p warrants further investigation as a potential regulator that may help inhibit or alleviate BPH.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.